Abbott Laboratories (ABT)vsBristol-Myers Squibb Company (BMY)
ABT
Abbott Laboratories
$104.83
+0.74%
HEALTHCARE · Cap: $180.82B
BMY
Bristol-Myers Squibb Company
$58.94
+2.70%
HEALTHCARE · Cap: $120.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Bristol-Myers Squibb Company generates 9% more annual revenue ($48.19B vs $44.33B). ABT leads profitability with a 14.7% profit margin vs 14.6%. ABT appears more attractively valued with a PEG of 1.52. BMY earns a higher WallStSmart Score of 64/100 (C+).
ABT
Buy51
out of 100
Grade: C-
BMY
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-315.5%
Fair Value
$25.23
Current Price
$104.83
$79.60 premium
Margin of Safety
+63.0%
Fair Value
$161.93
Current Price
$58.94
$102.99 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.6%
Generating 2.6B in free cash flow
Every $100 of equity generates 40 in profit
Large-cap with strong market position
Attractively priced relative to earnings
Strong operational efficiency at 28.2%
Generating 1.6B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.4% revenue growth
Weak financial health signals
Expensive relative to growth rate
1.3% revenue growth
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : BMY
The strongest argument for BMY centers on Return on Equity, Market Cap, P/E Ratio.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : BMY
The primary concerns for BMY are PEG Ratio, Revenue Growth, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABT carries more volatility with a beta of 0.74 — expect wider price swings.
ABT is growing revenue faster at 4.4% — sustainability is the question.
ABT generates stronger free cash flow (2.6B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BMY scores higher overall (64/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Bristol-Myers Squibb Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?